Description: Taisho Pharmaceutical Holdings Co., Ltd., through its subsidiaries, researches, develops, manufactures, and sells over-the-counter (OTC) drugs and prescription pharmaceuticals in Japan and internationally. It operates in two segments, Self-Medication Operation Group and Prescription Pharmaceutical Operation Group. The Self-Medication Operation Group segment offers OTC drugs, quasi-drugs, food products, and general medical and hygiene supplies, such as Lipovitan series of energy drinks; the Pabron series of cold remedies and sinus treatments, as well as gargles, hand-washing treatments, and face masks; the RiUP series of hair re-growth treatment products; the Taisho Kampo Ichoyaku series of gastrointestinal treatment products; the Colac series of laxative products; and Livita series of food products for specialized health use, as well as engages in the real estate leasing and facility management, and hotel management operations. The Prescription Pharmaceutical Operation Group segment offers ethical drugs, including ZOSYN, an injectable antibiotic; Edirol, an active vitamin D3 osteoporosis agent; Clarith, a macrolide antibiotic; Palux, a peripheral vasodilator; OZEX and Geninax, quinolone antibacterial; Bonviva, a bisphosphonate antiresorptive agent; Biofermin, a live lactobacillus preparation; Lusefi, a type 2 diabetes mellitus agent; and LOQOA, a transdermal anti-inflammatory analgesic. This segment has various products under development primarily in therapeutic areas, such as central nervous system, infectious, and metabolic diseases, as well as orthopedic disorders. The company also offers raw materials for pharmaceuticals and quasi-drugs; and supplies health foods and skin care products. Taisho Pharmaceutical Holdings Co., Ltd. was founded in 1912 and is headquartered in Tokyo, Japan.
Home Page: www.taisho-holdings.co.jp
3-24-1 Takada
Tokyo,
170-8655
Japan
Phone:
81 3 3985 2020
Officers
| Name | Title |
|---|---|
| Mr. Akira Uehara | CEO & Representative Director |
| Mr. Shigeru Uehara | Executive VP & Director |
| Shinichi Tanaka | General Manager of Corporate Communications |
| Mr. Ken Uehara | MD & Executive Director |
| Mr. Tetsu Watanabe | Executive Director |
| Mr. Jun Kuroda | Executive VP & Director |
Exchange: PINK
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 36.4964 |
|---|---|
| Trailing PE: | 70.5882 |
| Price-to-Book MRQ: | 0.5539 |
| Price-to-Sales TTM: | 0.0135 |
| IPO Date: | |
| Fiscal Year End: | March |
| Full Time Employees: | 8784 |